daunorubicinol

Subscribe to Selected New Research on daunorubicinol

17 relevant articles (0 outcomes, 2 trials/studies) found for this Bio-Agent

Description: main metabolite of daunomycin; structure; RN given refers to parent cpd.

Also Known As:

13-dihydrodaunorubicin; daunomycinol; daunorubicinol hydrochloride; dihydrodaunomycin; duborimycin; leukaemomycin D; RP 20798 /OD/ 20798 RP

Bio-Agent Context: Research Results

Experts

1.	Poz, D: 1 article (10/2007)
2.	Tomezzoli, A: 1 article (10/2007)
3.	de Manzoni, G: 1 article (10/2007)
4.	Furlanut, M: 1 article (10/2007)
5.	Pasini, F: 1 article (10/2007)
6.	Franceschi, L: 1 article (10/2007)
7.	Tasselli, S: 1 article (10/2007)
8.	Troost, D: 1 article (07/2001)
9.	Albrecht, K W: 1 article (07/2001)
10.	Kaaijk, P: 1 article (07/2001)

Related Diseases

1.	Neoplasms (Cancer) 09/18/2007 - "The resulting alcohol metabolite daunorubicinol has a far less anti-tumor potency and, in addition, is responsible for the life-threatening cardiac toxicity that limits the clinical use of DRC" 07/01/2001 - "In samples taken from tumor, tumor-edge and where possible from adjacent brain, the levels of Daunorubicin and its active metabolite Daunorubicinol were assessed with high performance liquid chromatography" 01/01/1976 - "Duborimycin is a new antimitotic agent approaching danorubicin and adriamycin in activity which has been tried on 151 patients suffering from cancer of different types, is an advanced local/regional stage and/or metastatic disease" 01/01/1999 - "Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin." 01/01/1976 - "However, the first results obtained by this line of approach, notably in chemo-resistant forms of tumour such as melanoma and sarcomas, utilizing the very strict criteria in one analysis encourage further study of duborimycin in cases of this sort (preferably in association and in accordance with protocols of comparative trials) so that its place in cancer chemotherapy may be more precisely defined." Get all the results and reference details, order at left...
2.	Melanoma (Melanoma, Malignant) 01/01/1976 - "However, the first results obtained by this line of approach, notably in chemo-resistant forms of tumour such as melanoma and sarcomas, utilizing the very strict criteria in one analysis encourage further study of duborimycin in cases of this sort (preferably in association and in accordance with protocols of comparative trials) so that its place in cancer chemotherapy may be more precisely defined." 01/01/1978 - "Adding duborimycin to the association of vincristine + DTIC in the treatment of malignant melanoma produces therapeutic results interesting but not statistically significant and not counter-balancing the toxic side effects" Get all the results and reference details, order at left...
3.	Sarcoma (Soft Tissue Sarcoma) 01/01/1976 - "However, the first results obtained by this line of approach, notably in chemo-resistant forms of tumour such as melanoma and sarcomas, utilizing the very strict criteria in one analysis encourage further study of duborimycin in cases of this sort (preferably in association and in accordance with protocols of comparative trials) so that its place in cancer chemotherapy may be more precisely defined." Get all the results and reference details, order at left...
4.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/01/1988 - "In an attempt to identify pharmacokinetic factors that determine the response of acute myeloid leukemia (AML) patients to induction chemotherapy, we determined the concentrations of daunorubicin (DNR) and the main metabolite daunorubicinol (DOL) in vivo and particularly evaluated the concentrations in blood and bone marrow nucleated cells" 01/01/1986 - "Critical technical parameters to establish a reliable method for quantifying the intracellular content of anthracyclines were evaluated in patients with acute myelocytic leukemia (AML); two methods were used for the isolation of leukocytes from the peripheral blood and two methods, for the extraction of daunorubicin (DNR), daunorubicinol (DOL), and doxorubicin (DOX) from these cells, followed by drug analysis using high-performance liquid chromatography (HPLC)" Get all the results and reference details, order at left...
5.	Lymphoid Leukemia 01/01/1980 - "In two patients with acute non-lymphocytic leukemia, leukemic cell as well as plasma concentrations of Daunorubicin (D) and Daunorubicinol (DOH) were studied after administration of D as free drug or as a complex with DNA" 01/01/1980 - "In two patients with acute non-lymphocytic leukemia, leukemic cell as well as plasma concentrations of Daunorubicin (D) and Daunorubicinol (DOH) were studied after administration of D as free drug or as a complex with DNA" Get all the results and reference details, order at left...
13 Diseases and 17 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Daunorubicin (Cerubidine)
2.	Doxorubicin (Adriamycin)
3.	zorubicin
4.	Oxidoreductases
5.	DNA (Deoxyribonucleic Acid)
6.	Multidrug Resistance-Associated Proteins
7.	P-Glycoprotein
8.	Anthracyclines
9.	Idarubicin (4 Demethoxydaunorubicin)
10.	Vincristine (Oncovin)
13 Drugs and Important Bio-Agents and 16 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
1 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>